Efficient Non-Viral Ocular Gene Transfer with Compacted DNA Nanoparticles
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The eye is an excellent candidate for gene therapy as it is immune privileged and much of the disease-causing genetics are well understood. Towards this goal, we evaluated the efficiency of compacted DNA nanoparticles as a system for non-viral gene transfer to ocular tissues. The compacted DNA nanoparticles examined here have been shown to be safe and effective in a human clinical trial, have no theoretical limitation on plasmid size, do not provoke immune responses, and can be highly concentrated. METHODS AND FINDINGS: Here we show that these nanoparticles can be targeted to different tissues within the eye by varying the site of injection. Almost all cell types of the eye were capable of transfection by the nanoparticle and produced robust levels of gene expression that were dose-dependent. Most impressively, subretinal delivery of these nanoparticles transfected nearly all of the photoreceptor population and produced expression levels almost equal to that of rod opsin, the highest expressed gene in the retina. CONCLUSIONS: As no deleterious effects on retinal function were observed, this treatment strategy appears to be clinically viable and provides a highly efficient non-viral technology to safely deliver and express nucleic acids in the retina and other ocular tissues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Administration of CMV.eGFPDNA incorporated into nanoparticles showed robust expression in the retina after two days, but the expression was not detectable after two weeks [59].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [59]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Single-molecule DNA nanoparticles compacted by polyethylene glycol (PEG)-substituted lysine peptides (CK30-PEG) have been used to carry payloads up to 20 kb in size,82,83 with several groups demonstrating their safety in BALB/c mice and rds+/− Rho-/- or Abca4-/- mouse models of retinal degeneration.82–86”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [83]
Experimental — accuracy not yet measuredIn the citing paper
“In addition to phagocytosing photoreceptor outer segments in vivo, RPE can take up large naked DNA or DNA NPs by phagocytosis [26,27].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Complement factor H polymorphism in age-related macular degeneration
Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J.-Y., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., et al. (2005) · Science · doi:10.1126/science.1109557 · Cited by 4,492
Progress and problems with the use of viral vectors for gene therapy
Thomas, C. E., Ehrhardt, A., & Kay, M. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1066 · Cited by 2,501 · cited 1×
“Although viral vectors also have been successful in alleviating hereditary retinal degeneration in mice [12,21], they can be limited by cell tropism, the size of the expression cassette to be transferred, and host immunity to repeat infections [22,23].”
BackgroundComplement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449
Complement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424 · cited 1×
“[55–58].”
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588 · cited 1×
“recurring injections to maintain this inhibitory effect [59–61].”
BackgroundRaper, S. E., Chirmule, N., Lee, F. S., Wivel, N. A., Bagg, A., Gao, G.-P., Wilson, J. M., & Batshaw, M. L. (2003) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.08.016 · Cited by 1,498 · cited 1×
“Additionally, concerns regarding the safety of using viral vectors in human patients have been raised and some trials have resulted in oncogenesis or even mortality [22,24–26].”
BackgroundIdentification of a Gene That Causes Primary Open Angle Glaucoma
Stone, E. M., Fingert, J. H., Alward, W. L. M., Nguyen, T. D., Polansky, J. R., Sunden, S. L. F., Nishimura, D., Clark, A. F., Nystuen, A., Nichols, B. E., et al. (1997) · Science · doi:10.1126/science.275.5300.668 · Cited by 1,433 · cited 1×
“Many disease-causing mutations and their contribution to the pathogenesis of ocular diseases including cataracts, glaucoma, and retinitis pigmentosa have been well characterized [1–5].”
BackgroundGene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202 · cited 1×
“Bennett and colleagues used adeno-associated virus to express the RPE65 cDNA which restored retinal function and has successfully persisted over 3 years [18–20].”
MethodOtt, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Bi, A., Cui, J., Ma, Y.-P., Olshevskaya, E., Pu, M., Dizhoor, A. M., & Pan, Z.-H. (2006) · Neuron · doi:10.1016/j.neuron.2006.02.026 · Cited by 771 · cited 1×
“lacking photoreceptors [52].”
Retinal angiogenesis in development and disease
Gariano, R. F., & Gardner, T. W. (2005) · Nature · doi:10.1038/nature04482 · Cited by 705 · cited 1×
“recurring injections to maintain this inhibitory effect [59–61].”
BackgroundMutations in RPE65 cause Leber's congenital amaurosis
Marlhens, F., Bareil, C., Griffoin, J.-M., Zrenner, E., Amalric, P., Eliaou, C., Liu, S.-Y., Harris, E., Redmond, T. M., Arnaud, B., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-139 · Cited by 606 · cited 1×
“Perhaps the most encouraging trial has occurred in Briard dogs harboring a naturally occurring mutation in the RPE65 gene, which causes visual impairment similar to Early Onset Severe Retinal Dystrophy in humans [16,17].”
BackgroundOncomodulin is a macrophage-derived signal for axon regeneration in retinal ganglion cells
Yin, Y., Henzl, M. T., Lorber, B., Nakazawa, T., Thomas, T. T., Jiang, F., Langer, R., & Benowitz, L. I. (2006) · Nature Neuroscience · doi:10.1038/nn1701 · Cited by 515 · cited 1×
“For other types of optic nerve injuries, the production of oncomodulin by DNA nanoparticles could be a practical approach for regenerating damaged axons [51].”
BackgroundAcland, G. M., Aguirre, G. D., Bennett, J., Aleman, T. S., Cideciyan, A. V., Bennicelli, J., Dejneka, N. S., Pearce-Kelling, S. E., Maguire, A. M., Palczewski, K., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.008 · Cited by 477 · cited 1×
“Bennett and colleagues used adeno-associated virus to express the RPE65 cDNA which restored retinal function and has successfully persisted over 3 years [18–20].”
MethodLewin, A. S., Drenser, K. A., Hauswirth, W. W., Nishikawa, S., Yasumura, D., Flannery, J. G., & LaVail, M. M. (1998) · Nature Medicine · doi:10.1038/nm0898-967 · Cited by 407
Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus
Flannery, J. G., Zolotukhin, S., Vaquero, M. I., LaVail, M. M., Muzyczka, N., & Hauswirth, W. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6916 · Cited by 407
Brooks, A. R., Harkins, R. N., Wang, P., Qian, H. S., Liu, P., & Rubanyi, G. M. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.516 · Cited by 362 · cited 1×
“We focused on characterizing the effects of gene transfer at 2-days post-injection as this was the peak of reporter gene expression we observed and the CMV promoter used is known to be silenced as early as 1 to 2 days post-transfection [40–42].”
Martin, K. R. G., Quigley, H. A., Zack, D. J., Levkovitch-Verbin, H., Kielczewski, J., Valenta, D., Baumrind, L., Pease, M. E., Klein, R. L., & Hauswirth, W. W. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-1332 · Cited by 362 · cited 1×
“Specifically, delivery of brain derived neurotrophic factor (BDNF) had a protective effect in animal models of glaucoma [50].”
BackgroundMutagenesis and Oncogenesis by Chromosomal Insertion of Gene Transfer Vectors
Baum, C., Kustikova, O., Modlich, U., Li, Z., & Fehse, B. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.253 · Cited by 360 · cited 1×
“Additionally, concerns regarding the safety of using viral vectors in human patients have been raised and some trials have resulted in oncogenesis or even mortality [22,24–26].”
BackgroundPhotoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy
Bennett, J., Tanabe, T., Sun, D., Zeng, Y., Kjeldbye, H., Gouras, P., & Maguire, A. M. (1996) · Nature Medicine · doi:10.1038/nm0696-649 · Cited by 316 · cited 1×
“Although viral vectors also have been successful in alleviating hereditary retinal degeneration in mice [12,21], they can be limited by cell tropism, the size of the expression cassette to be transferred, and host immunity to repeat infections [22,23].”
BackgroundAli, R. R., Sarra, G.-M., Stephens, C., Alwis, M. D., Bainbridge, J. W. B., Munro, P. M., Fauser, S., Reichel, M. B., Kinnon, C., Hunt, D. M., et al. (2000) · Nature Genetics · doi:10.1038/77068 · Cited by 304 · cited 1×
“Many attempts to rescue genetic deficits with viral gene therapy have proven effective in the eye [11–15].”
BackgroundKonstan, M. W., Davis, P. B., Wagener, J. S., Hilliard, K. A., Stern, R. C., Milgram, L. J. H., Kowalczyk, T. H., Hyatt, S. L., Fink, T. L., Gedeon, C. R., et al. (2004) · Human Gene Therapy · doi:10.1089/hum.2004.15.1255 · Cited by 298 · cited 1×
“Another study demonstrated the efficacy and safety of this methodology in human subjects [32].”
BackgroundSelf-citationBerry, V., Francis, P., Kaushal, S., Moore, A., & Bhattacharya, S. (2000) · Nature Genetics · doi:10.1038/75538 · Cited by 287 · cited 1×
“Many disease-causing mutations and their contribution to the pathogenesis of ocular diseases including cataracts, glaucoma, and retinitis pigmentosa have been well characterized [1–5].”
BackgroundAguirre, G. K., Baldwin, V. J., Pearce‐Kelling, S., Narfström, K. L., Ray, K., & Acland, G. M. (1998) · PubMed · Cited by 244
Bennett, J., Maguire, A. M., Cideciyan, A. V., Schnell, M., Glover, E., Anand, V., Aleman, T. S., Chirmule, N., Gupta, A. R., Huang, Y., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9920 · Cited by 242 · cited 1×
“This observation is common in the FITC channel of retinal cryosections as the photoreceptor OSs are packed tightly with the opsin protein which causes this natural autofluorescence [36–38].”
BackgroundSilencing of episomal transgene expression by plasmid bacterial DNA elements in vivo
Chen, Z. Y., He, C. Y., Meuse, L., & Kay, M. A. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302231 · Cited by 231 · cited 1×
“We focused on characterizing the effects of gene transfer at 2-days post-injection as this was the peak of reporter gene expression we observed and the CMV promoter used is known to be silenced as early as 1 to 2 days post-transfection [40–42].”
Halbert, C. L., Miller, A. D., Mcnamara, S., Emerson, J., Gibson, R. L., Ramsey, B., & Aitken, M. L. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.440 · Cited by 227 · cited 1×
“Although viral vectors also have been successful in alleviating hereditary retinal degeneration in mice [12,21], they can be limited by cell tropism, the size of the expression cassette to be transferred, and host immunity to repeat infections [22,23].”
BackgroundFarrar, G. J. (2002) · The EMBO Journal · doi:10.1093/emboj/21.5.857 · Cited by 203 · cited 1×
“Many disease-causing mutations and their contribution to the pathogenesis of ocular diseases including cataracts, glaucoma, and retinitis pigmentosa have been well characterized [1–5].”
Nanoparticles of Compacted DNA Transfect Postmitotic Cells
Liu, G., Li, D., Pasumarthy, M. K., Kowalczyk, T. H., Gedeon, C. R., Hyatt, S. L., Payne, J. M., Miller, T. J., Brunovskis, P., Fink, T. L., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305776200 · Cited by 190 · cited 1×
“These nanoparticles consist of a neutrally-charged complex containing a single molecule of plasmid DNA compacted with polyethylene glycol (PEG)-substituted lysine peptides [27].”
BackgroundSelf-citationZareparsi, S., Buraczynska, M., Branham, K. E. H., Shah, S., Eng, D., Li, M., Pawar, H., Yashar, B. M., Moroi, S. E., Lichter, P. R., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi154 · Cited by 190
Vitreous: A Barrier to Nonviral Ocular Gene Therapy
Peeters, L., Sanders, N. N., Braeckmans, K., Boussery, K., Van de Voorde, J., De Smedt, S. C., & Demeester, J. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0165 · Cited by 189 · cited 1×
“vitreous as a barrier to gene transfer [53], however the”
BackgroundRosenfeld, P. J., Heier, J. S., Hantsbarger, G., & Shams, N. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.01.027 · Cited by 189 · cited 1×
“recurring injections to maintain this inhibitory effect [59–61].”
Background(1998) · PubMed · Cited by 173
Transfection of airway epithelium by stable PEGylated poly-l-lysine DNA nanoparticles in vivo
Ziady, A.-G., Gedeon, C. R., Miller, T., Quan, W., Payne, J. M., Hyatt, S. L., Fink, T. L., Muhammad, O., Oette, S., Kowalczyk, T., et al. (2003) · Molecular Therapy · doi:10.1016/j.ymthe.2003.07.007 · Cited by 165 · cited 2×
“DNA nanoparticles were formulated by mixing plasmid DNA with CK30PEG10K, a 30-mer lysine peptide with an N-terminal cysteine that is conjugated via a maleimide linkage to 10 kDa polyethylene glycol, as previously described [29].”
BackgroundMethodSelf-citationLiu, G., Molas, M., Grossmann, G. A., Pasumarthy, M., Perales, J. C., Cooper, M. J., & Hanson, R. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105250200 · Cited by 160 · cited 2×
“1 (5,147 bp) encodes the enhanced green fluorescent protein cDNA transcriptionally-controlled by the CMV immediate-early promoter and enhancer, as previously described [33].”
BackgroundMethodSelf-citationFink, T. L., Klepcyk, P. J., Oette, S. M., Gedeon, C. R., Hyatt, S. L., Kowalczyk, T. H., Moen, R. C., & Cooper, M. J. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302761 · Cited by 139 · cited 1×
“[30].”
Self-citationBatten, M. L., Imanishi, Y., Tu, D. C., Doan, T., Zhu, L., Pang, J., Glushakova, L., Moise, A. R., Baehr, W., Van Gelder, R. N., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020333 · Cited by 134 · cited 1×
“In addition, several treatment strategies for overcoming these genetic deficits have been attempted and proven in tissue culture and various animal models [6–10].”
Sarra, G.-M. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.21.2353 · Cited by 128 · cited 1×
“In addition, several treatment strategies for overcoming these genetic deficits have been attempted and proven in tissue culture and various animal models [6–10].”
BackgroundMohan, R. R., Sharma, A., Netto, M. V., Sinha, S., & Wilson, S. E. (2005) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2005.04.001 · Cited by 108 · cited 1×
“Expression of inflammatory regulators and siRNA may also be effective modes of treating infectious diseases affecting the cornea [46,47].”
BackgroundRecombinant AAV-mediated gene transfer to the retina: gene therapy perspectives
Rolling, F. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302366 · Cited by 100 · cited 1×
“strategies have already been developed [4,11,15,54].”
Adeno-Associated Virus-Vectored Gene Therapy for Retinal Disease
Dinculescu, A., Glushakova, L., Min, S.-H., & Hauswirth, W. W. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.649 · Cited by 100 · cited 1×
“strategies have already been developed [4,11,15,54].”
Minimal toxicity of stabilized compacted DNA nanoparticles in the murine lung
Ziady, A.-G., Gedeon, C. R., Muhammad, O., Stillwell, V., Oette, S. M., Fink, T. L., Quan, W., Kowalczyk, T. H., Hyatt, S. L., Payne, J., et al. (2003) · Molecular Therapy · doi:10.1016/j.ymthe.2003.09.002 · Cited by 93 · cited 1×
“decrement in biologic activity [27–29].”
Self-citationRetention of function without normal disc morphogenesis occurs in cone but not rod photoreceptors
Farjo, R., Skaggs, J. S., Nagel, B. A., Quiambao, A. B., Nash, Z. A., Fliesler, S. J., & Naash, M. I. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200509036 · Cited by 92 · cited 3×
“Tissue fixation and sectioning were performed as previously described [34].”
MethodInfluentialSelf-citationRibozyme-targeted destruction of RNA associated with autosomal-dominant retinitis pigmentosa.
Drenser, K. A., Timmers, A. M., Hauswirth, W. W., & Lewin, A. S. (1998) · PubMed · Cited by 86
RPE65 Gene Delivery Restores Isomerohydrolase Activity and Prevents Early Cone Loss in Rpe65−/−Mice
Chen, Y., Moiseyev, G., Takahashi, Y., & Ma, J.-X. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0965 · Cited by 80 · cited 1×
“Many attempts to rescue genetic deficits with viral gene therapy have proven effective in the eye [11–15].”
BackgroundA Single, Abbreviated RPGR-ORF15 Variant Reconstitutes RPGR Function In Vivo
Hong, D.-H., Pawlyk, B. S., Adamian, M., Sandberg, M. A., & Li, T. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-1065 · Cited by 75 · cited 1×
“Although viral vectors also have been successful in alleviating hereditary retinal degeneration in mice [12,21], they can be limited by cell tropism, the size of the expression cassette to be transferred, and host immunity to repeat infections [22,23].”
BackgroundAssessment of Structure and Function Over a 3-year Period after Gene Transfer in RPE65−/− dogs
Narfström, K. L., Vaegan, Katz, M. L., Bragadóttir, R., Rakoczy, E. P., & Seeliger, M. W. (2005) · Documenta Ophthalmologica · doi:10.1007/s10633-005-3159-0 · Cited by 67 · cited 1×
“Bennett and colleagues used adeno-associated virus to express the RPE65 cDNA which restored retinal function and has successfully persisted over 3 years [18–20].”
MethodGene therapy for optic nerve disease
Martin, K. R. G., & Quigley, H. A. (2004) · Eye · doi:10.1038/sj.eye.6701579 · Cited by 62 · cited 1×
“Therefore, these methodologies might be suitable for treating multiple optic nerve diseases, including optic neuritis, Leber’s hereditary optic neuropathy, and glaucoma [48,49].”
BackgroundMartin, A. C., Thornton, J. D., Liu, J., Wang, X., Zuo, J., Jablonski, M. M., Chaum, E., Zindy, F., & Skapek, S. X. (2004) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.04-0349 · Cited by 60 · cited 1×
“This observation is common in the FITC channel of retinal cryosections as the photoreceptor OSs are packed tightly with the opsin protein which causes this natural autofluorescence [36–38].”
BackgroundInsights into X-linked retinitis pigmentosa type 3, allied diseases and underlying pathomechanisms
Ferreira, P. A. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi272 · Cited by 56 · cited 1×
“strategies have already been developed [4,11,15,54].”
Prospects for gene therapy in corneal disease
Jun, A. S., & Larkin, F. (2003) · Eye · doi:10.1038/sj.eye.6700565 · Cited by 52 · cited 1×
“Expression of inflammatory regulators and siRNA may also be effective modes of treating infectious diseases affecting the cornea [46,47].”
BackgroundTowards mutation-independent silencing of genes involved in retinal degeneration by RNA interference
Cashman, S. M., Binkley, E. A., & Kumar‐Singh, R. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302512 · Cited by 47
Nour, M., Quiambao, A. B., Peterson, W. M., Al-Ubaidi, M. R., & Naash, M. I. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.03-0453 · Cited by 45 · cited 1×
“To target nanoparticle driven expression of EGFP in the photoreceptors and RPE, we delivered 1 µL of AC-GFP, TFA-GFP, or naked plasmid to the retina by a subretinal injection. Our laboratory has previously demonstrated this method is capable of delivering material to over 90% of the photoreceptor cells”
MethodSelf-citationCommentary: An Aye for Eye Gene Therapy
Bennett, J. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.177 · Cited by 19 · cited 1×
“In addition, several treatment strategies for overcoming these genetic deficits have been attempted and proven in tissue culture and various animal models [6–10].”
BackgroundAbsence of Functional and Structural Abnormalities Associated with Expression of EGFP in the Retina
Nour, M., Quiambao, A. B., Al-Ubaidi, M. R., & Naash, M. I. (2004) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.03-0663 · Cited by 16 · cited 1×
“Tissue fixation and sectioning were performed as previously described [35].”
MethodSelf-citationBauer, S., Maier, S. K. G., Neyses, L., & Maass, A. H. (2005) · DNA and Cell Biology · doi:10.1089/dna.2005.24.381 · Cited by 14 · cited 1×
“We focused on characterizing the effects of gene transfer at 2-days post-injection as this was the peak of reporter gene expression we observed and the CMV promoter used is known to be silenced as early as 1 to 2 days post-transfection [40–42].”
397. Compacted DNA Nanoparticles Transfect Cells by Binding to Cell Surface Nucleolin
Chen, X., & Davis, P. B. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.08.459 · Cited by 8
p21WAF-1/Cip-1 gene therapy as an adjunct to glaucoma filtration surgery.
Atencio, I. A., Chen, Z., Nguyen, Q. H., Faha, B., & Maneval, D. C. (2004) · PubMed · Cited by 6
882. Non-Viral Ocular Gene Transfer for Hereditary Retinal Degeneration
Naash, M. I., Ballard, R. M., Skaggs, J. S., Nash, Z. A., Quiambao, A. B., Cooper, M. J., & Farjo, R. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.08.971 · Cited by 5
Self-citation(2003) · Molecular Therapy · doi:10.1016/s1525-0016(16)41407-3 · Cited by 4
Research works printed but not linked: 1
- TH Kowalczyk, 2001, Type of polylysine counterion influences morphology and biological function of condensed DNA., Mol Ther, 3, S359
Cited by
Nonviral Gene Delivery: Principle, Limitations, and Recent Progress
Al-Dosari, M. S., & Gao, X. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9143-y · Cited by 706
“In addition to systemic application, significant efforts have been made for topical and regional gene and siRNA delivery with lipoplexes to respiratory mucosa and airway epithelial cells for the treatment of cystic fibrosis, acute lung injuries (79), as well as to cornea tissues for degenerative ocular diseases (80).”
Current and future ophthalmic drug delivery systems
del Amo, E. M., & Urtti, A. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.11.002 · Cited by 414
Cuenca, N., Fernández-Sánchez, L., Campello, L., Maneu, V., De la Villa, P., Lax, P., & Pinilla, I. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.07.001 · Cited by 401
“DNA nanoparticles (Conley and Naash, 2010; Farjo et al., 2006), the fC31 integrase system (Chalberg et al.”
Applications of nanoparticles in ophthalmology
Diebold, Y., & Calonge, M. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.08.002 · Cited by 392
Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo
Xu, Q., Boylan, N. J., Suk, J. S., Wang, Y.-Y., Nance, E. A., Yang, J.-C., McDonnell, P. J., Cone, R. A., Duh, E. J., & Hanes, J. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.01.018 · Cited by 326
“Their rapid penetration through vitreous meshwork may at least partly account for the successful gene delivery to the retina following the intravitreal injection in mice [46].”
Background
Metadata
- Authors
- Farjo, R., Skaggs, J., Quiambao, A. B., Cooper, M. J., & Naash, M. I.
- Affiliations
- University of Oklahoma Health Sciences Center (US)
- Copernicus Therapeutics (United States) (US)
- Corresponding author
- Naash, Muna I.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2006-12-20
- Volume
- 1
- Issue
- 1
- Pages
- e38
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC1762345
- OpenAlex
- W2075139742
- Cited by
- 208
- References
- 60
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 4 · 2023: 10 · 2022: 4 · 2021: 9 · 2020: 8 · 2019: 3 · 2018: 9 · 2017: 12 · 2016: 11 · 2015: 14 · 2014: 17 · 2013: 14 · 2012: 18
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Foundation Fighting Blindness
- Research to Prevent Blindness
- Oklahoma Center for the Advancement of Science and Technology
- National Institutes of Health (EY12190)
- National Eye Institute (P30EY012190, R56EY010609, R03EY016201, EY10609, EY016201, R01EY010609)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- non-viral gene delivery, ocular gene therapy, subretinal injection, retinal gene delivery, immune privilege, ocular tissues
- MeSH terms
- Animals, Base Sequence, DNA, Recombinant, Drug Carriers, Eye, Humans, Mice, Inbred BALB C, Microscopy, Fluorescence, Recombinant Proteins, Retina, RNA, Messenger, Tissue Distribution, Transfection, Genetic Therapy, Gene Expression, DNA Primers, Gene Transfer Techniques, Green Fluorescent Proteins, Mice, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.